Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans (DOXY)
Primary Purpose
Type 2 Diabetes, Obesity
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Doxycycline
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring doxycycline, insulin resistance, obesity, inflammation
Eligibility Criteria
Inclusion Criteria:
- Ambulatory, medically stable, able to give informed consent, and comply with the protocol.
- Obesity with BMI >30 kg/m2.
- DM2 for less than 10 years.
- 7.5% < HA1C < 10%
- Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)
Exclusion Criteria:
- Mental states that would preclude complete understanding of the protocol and compliance.
- Chronic illness such as renal failure (with creatinine clearance <80 ml/min for Specific Aim 2).
- Women of child-bearing age because of the potential hazard to the fetus (doxycycline may cause permanent discoloration of the teeth and deposition in bone inhibiting growth) and because doxycycline may render oral contraceptives less effective.
- Nursing mothers.
- Allergy to tetracyclines.
- Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant therapy, antacids containing aluminum, calcium, or magnesium, iron-containing preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or methoxyflurane, thiazolidinediones (TZD)
Sites / Locations
- University of California San Diego Clinical trials Research Institute
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Doxycycline
Placebo
Arm Description
Participants with DM2 receiving doxycycline 100mg BID
Pills prepared identical to doxycycline.
Outcomes
Primary Outcome Measures
MMP Activity
MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9.
MMP Activity
MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.
Secondary Outcome Measures
CRP
Measure of global inflammation.
CRP
Measure of global inflammation. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.
Full Information
NCT ID
NCT01375491
First Posted
May 25, 2011
Last Updated
January 8, 2020
Sponsor
University of California, San Diego
Collaborators
Ruth L. Kirschstein National Research Service Award, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR)
1. Study Identification
Unique Protocol Identification Number
NCT01375491
Brief Title
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
Acronym
DOXY
Official Title
Blockade of Receptor Cleavage in Diabetes Mellitus With an MMP Inhibitor
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Diego
Collaborators
Ruth L. Kirschstein National Research Service Award, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).
Detailed Description
Design and Setting: 84 day (D84), double-blind, randomized, placebo (PL)-controlled clinical trial conducted in an academic tertiary care center.
Patients: Non-DM2 Controls (n=15); participants with DM2 receiving PL (n=13) or DOX (n=11).
Interventions: All participants were evaluated at day 1 (D1); those with DM2 were also evaluated at D84 after DOX 100mg twice daily or PL.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Obesity
Keywords
doxycycline, insulin resistance, obesity, inflammation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
39 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Doxycycline
Arm Type
Experimental
Arm Description
Participants with DM2 receiving doxycycline 100mg BID
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Pills prepared identical to doxycycline.
Intervention Type
Drug
Intervention Name(s)
Doxycycline
Other Intervention Name(s)
Vibramycin
Intervention Description
generic doxycycline 100mg twice daily
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo comparator to doxycycline
Primary Outcome Measure Information:
Title
MMP Activity
Description
MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9.
Time Frame
Baseline (Day 1)
Title
MMP Activity
Description
MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.
Time Frame
Day 84
Secondary Outcome Measure Information:
Title
CRP
Description
Measure of global inflammation.
Time Frame
Baseline (Day 1)
Title
CRP
Description
Measure of global inflammation. Only the Doxycycline and Placebo arms are reported because the control group was not evaluated at Day 84.
Time Frame
Day 84
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Ambulatory, medically stable, able to give informed consent, and comply with the protocol.
Obesity with BMI >30 kg/m2.
DM2 for less than 10 years.
7.5% < HA1C < 10%
Taking insulin and/or oral medications (biguanide, sulfonlylurea, etc.)
Exclusion Criteria:
Mental states that would preclude complete understanding of the protocol and compliance.
Chronic illness such as renal failure (with creatinine clearance <80 ml/min for Specific Aim 2).
Women of child-bearing age because of the potential hazard to the fetus (doxycycline may cause permanent discoloration of the teeth and deposition in bone inhibiting growth) and because doxycycline may render oral contraceptives less effective.
Nursing mothers.
Allergy to tetracyclines.
Subjects taking the following drugs: penicillin or it's derivatives, anticoagulant therapy, antacids containing aluminum, calcium, or magnesium, iron-containing preparations, bismuth subsalicylate, barbiturates, carbamazepine, phenytoin or methoxyflurane, thiazolidinediones (TZD)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen L Herbst, PhD, MD
Organizational Affiliation
UCSD
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Diego Clinical trials Research Institute
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
18606910
Citation
DeLano FA, Schmid-Schonbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008 Aug;52(2):415-23. doi: 10.1161/HYPERTENSIONAHA.107.104356. Epub 2008 Jul 7.
Results Reference
background
PubMed Identifier
23025537
Citation
Frankwich K, Tibble C, Torres-Gonzalez M, Bonner M, Lefkowitz R, Tyndall M, Schmid-Schonbein GW, Villarreal F, Heller M, Herbst K. Proof of Concept: Matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm (Lond). 2012 Oct 1;9(1):35. doi: 10.1186/1476-9255-9-35.
Results Reference
result
Learn more about this trial
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
We'll reach out to this number within 24 hrs